Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Aug 9, 2018 | Series B | $60M | 2 | — | — | Detail |
Jan 6, 2017 | Series A | $5M | 2 | — | — | Detail |
Sep 30, 2015 | Series A | $35M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Inserm Transfert Initiative | — | Series B |
Versant Ventures | — | Series B |